Pharmicell Co: Q1 2025 revenue and profit soared on Bio-Chemical strength and robust R&D pipeline

About this update from Pharmicell Co., Ltd

Q1 2025 saw revenue surge to KRW 27.0 billion and net income reach KRW 8.5 billion, driven by strong Bio-Chemical sales and improved margins. R&D remains a focus, with multiple late-stage clinical trials and new production facilities supporting future growth.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Pharmicell Co., Ltd